Gene: KCNC1

3746
EPM7|KV3.1|KV4|NGK2
potassium voltage-gated channel subfamily C member 1
protein-coding
11p15.1
Ensembl:ENSG00000129159 MIM:176258 Vega:OTTHUMG00000166359 UniprotKB:P48547
NG_041827.1
PubMed|SNP Mapped
1   ANCO-SNPs
OD|ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.097e-1 (AD)  2.582e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs60349741chr11:17774564 (GRCh38.p7)A>C / A>Topioid dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ATP2B30.964
KCNB10.961
PRDM80.958
SLC12A50.956
LMTK20.956
PLXNA40.954
MAP3K90.954
ARHGAP440.953
AAK10.953
L1CAM0.953

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HEY2-0.605
MYL3-0.598
YES1-0.596
REST-0.584
COPZ2-0.575
MBNL3-0.566
SNHG18-0.562
RAI14-0.552
WWTR1-0.551
RAB13-0.55

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB06637DalfampridineSmall Molecule504-24-5ApprovedTarget
ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of KCNC1 mRNA"19114083
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA"27188386
D000535Aluminum[APP protein modified form binds to Aluminum] which results in decreased expression of KCNC1 mRNA21298039
D001151ArsenicArsenic affects the methylation of KCNC1 gene25304211
C015001arsenitearsenite results in increased methylation of KCNC1 promoter23974009
C006780bisphenol Abisphenol A results in decreased expression of KCNC1 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of KCNC1 gene28505145
C018475butyraldehydebutyraldehyde results in increased expression of KCNC1 mRNA26079696
D002104CadmiumCadmium results in decreased expression of KCNC1 mRNA24284285
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of KCNC1 gene20938992
D003471CuprizoneCuprizone results in decreased expression of KCNC1 mRNA26577399
D003840Deoxycholic Acid[gluconic acid co-treated with Deoxycholic Acid] results in increased expression of KCNC1 mRNA16556975
C024565ethylene dichlorideethylene dichloride results in increased expression of KCNC1 mRNA28189721
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of KCNC1 gene20938992
D019833Genistein[Genistein co-treated with Methoxychlor] results in decreased expression of KCNC1 mRNA21782745
D005839GentamicinsGentamicins results in decreased expression of KCNC1 mRNA22061828
C030691gluconic acid[gluconic acid co-treated with Deoxycholic Acid] results in increased expression of KCNC1 mRNA16556975
C030272maleic acidmaleic acid results in decreased expression of KCNC1 mRNA28392987
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of KCNC1 gene20938992
D008731Methoxychlor[Genistein co-treated with Methoxychlor] results in decreased expression of KCNC1 mRNA21782745
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of KCNC1 mRNA23179753
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of KCNC1 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of KCNC1 mRNA26272509
D010936Plant ExtractsPlant Extracts results in decreased expression of KCNC1 mRNA23557933
C531249Poly(amidoamine)Poly(amidoamine) analog results in decreased expression of KCNC1 mRNA23806026
D011188PotassiumKCNC1 protein affects the transport of Potassium18023363
D011189Potassium ChloridePotassium Chloride results in decreased expression of KCNC1 mRNA16412482
D011441PropylthiouracilPropylthiouracil results in decreased expression of KCNC1 mRNA24780913
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of KCNC1 mRNA23806026
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of KCNC1 mRNA25895662
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of KCNC1 mRNA26377647
D019789TetraethylammoniumTetraethylammonium results in decreased activity of KCNC1 protein10482766
D013779TetrodotoxinTetrodotoxin results in decreased expression of KCNC1 mRNA18775767
D014212TretinoinTretinoin results in decreased expression of KCNC1 mRNA21934132
C113580U 0126U 0126 results in decreased expression of KCNC1 protein18775767
D014635Valproic AcidValproic Acid affects the expression of KCNC1 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of KCNC1 mRNA23179753|2800136
D014635Valproic AcidValproic Acid results in increased methylation of KCNC1 gene29154799
D014639VanadiumVanadium results in decreased expression of KCNC1 mRNA19000753

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005249voltage-gated potassium channel activity-IBA21873635  
GO:0005249voltage-gated potassium channel activity-TAS8449507  
GO:0005251delayed rectifier potassium channel activity-IBA21873635  
GO:0005251delayed rectifier potassium channel activity-ISS-  
GO:0019894kinesin binding-IEA-  
GO:0044325ion channel binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006813potassium ion transport-TAS8449507  
GO:0009636response to toxic substance-IEA-  
GO:0009642response to light intensity-IEA-  
GO:0010996response to auditory stimulus-IEA-  
GO:0014075response to amine-IEA-  
GO:0021549cerebellum development-IEA-  
GO:0021759globus pallidus development-IEA-  
GO:0035690cellular response to drug-IEA-  
GO:0035864response to potassium ion-IEA-  
GO:0051260protein homooligomerization-IEA-  
GO:0051262protein tetramerization-IDA23734863  
GO:0071774response to fibroblast growth factor-IEA-  
GO:0071805potassium ion transmembrane transport-IBA21873635  
GO:0071805potassium ion transmembrane transport-ISS-  
GO:1903818positive regulation of voltage-gated potassium channel activity-IEA-  
GO:1990089response to nerve growth factor-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0008076voltage-gated potassium channel complex-IBA21873635  
GO:0008076voltage-gated potassium channel complex-IDA23734863  
GO:0008076voltage-gated potassium channel complex-ISS-  
GO:0009986cell surface-IEA-  
GO:0016021integral component of membrane-IBA21873635  
GO:0030424axon-IBA21873635  
GO:0030673axolemma-IEA-  
GO:0032590dendrite membrane-IBA21873635  
GO:0032590dendrite membrane-IEA-  
GO:0032809neuronal cell body membrane-IBA21873635  
GO:0032809neuronal cell body membrane-ISS-  
GO:0043025neuronal cell body-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemTAS
R-HSA-1296071Potassium ChannelsTAS
R-HSA-1296072Voltage gated Potassium channelsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24143882Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. (2014 Jul 1)Gelernter JBiol Psychiatry
25161819Genetic, psychosocial, and demographic factors associated with social disinhibition in Mexican-origin youth. (2014 Jul)Archer NPBrain Behav